This is a working overview of cold chain, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-06-15 and is reviewed periodically as new material appears.
The material is commonly handled as a lyophilized powder in sealed vials. The solid dissolves readily in water and in polar organic solvents, producing a clear solution after reconstitution. Light, heat and repeated freeze-thaw cycles are the concerns most often raised in handling guidance, because peptide bonds and the constrained ring can degrade. Working solutions are generally prepared fresh, and material left in solution is treated as less stable than the dry form. These properties shape how laboratories store and aliquot reference material.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography with ultraviolet detection, often paired with mass spectrometry. Retention time supports identity, while the mass spectrum confirms the molecular weight of the intact peptide. Purity is frequently reported as a percentage of total peak area, a figure that depends on the wavelength, column and gradient used. Impurity profiling may also look for truncated sequences, oxidised forms and residual counterions. Amino acid analysis and peptide mapping provide orthogonal confirmation when required.
Regulatory status varies by jurisdiction, and the substance is frequently described as unapproved for therapeutic use. Some authorities classify it alongside prescription-only medicines or controlled categories, while others address it through general consumer protection rules. Analytical surveys have reported mismatches between label claims and measured content in products sold online, although the scope of such testing is limited. Whether these discrepancies are widespread remains an open question. Discussion in the literature therefore tends to combine chemistry, supply-chain observation and policy analysis.
The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Typically supplied as a lyophilized solid in a sealed vial |
| Solubility class | Soluble in water and polar organic solvents | Reconstituted solutions are generally clear |
| Typical storage temperature | -20 degrees Celsius or below, dry | Protect from light; avoid repeated freeze-thaw cycles |
| Common analytical methods | Reversed-phase HPLC-UV, LC-MS | Used for purity estimation and mass confirmation |
| Reported purity range | Area percentage above 95 percent | Reporting practice and acceptance limits differ by laboratory |
Melanotan II holds no marketing authorisation from the Food and Drug Administration, the European Medicines Agency, the UK Medicines and Healthcare products Regulatory Agency or Australia's Therapeutic Goods Administration. Products sold under that name are treated as unapproved new drugs, and their sale or import is prohibited in several jurisdictions. Other countries classify the peptide as a prescription-only medicine or place it among controlled substances, so the legal position changes with the destination market. No pharmacopoeial monograph supplies an official specification, because the material is not a licensed pharmaceutical. Consequently, products offered online are not manufactured to a shared public standard.
The peer-reviewed record is dominated by small early-phase studies, case reports and pharmacovigilance summaries rather than large randomised trials. Papers typically examine tanning response, receptor selectivity or patterns of reported adverse events. Many note that participants obtained the peptide outside a clinical setting, which limits verification of composition and administered amount. Reported events vary widely, and causality is frequently unclear because the identity and purity of self-sourced material are unknown. Open questions include whether repeated melanocortin receptor stimulation produces cumulative effects, and how often label claims match actual content.
Identification in laboratories relies on reversed-phase liquid chromatography coupled with tandem mass spectrometry, with product-ion spectra compared against a certified reference standard. High-resolution mass spectrometry supplies accurate mass confirmation, and peptide mapping after enzymatic digestion separates melanotan II from closely related analogues. Quantitation of seized material is complicated by unknown counter-ions and residual trifluoroacetate left from purification. Immunoassays raised against alpha-melanocyte-stimulating hormone can cross-react, so chromatographic confirmation is normally required. Urinary detection windows are short, and reported limits of detection differ substantially between laboratories.
Melanocytes are the pigment-producing cells of the skin, and they carry melanocortin-1 receptors on their surface. When the receptor is activated, cyclic adenosine monophosphate rises inside the cell and raises the activity of enzymes such as tyrosinase, which increases melanin output. Melanotan-2 binds melanocortin-1 receptors in vitro and in animal models, and this binding is generally described as the basis for the tanning effect. Other receptors account for different effects: melanocortin-4 receptors contribute to appetite and erectile signalling, while melanocortin-3 and melanocortin-5 receptors contribute to energy balance and exocrine function.
Early published reports described melanotan-2 as a tanning agent without sun protection, which means darkening is not the same as protection against ultraviolet radiation. Later studies explored the peptide in erectile dysfunction, hemorrhagic shock, and some skin conditions. No regulator in the United States or Europe has approved it for clinical use. Many products labelled melanotan-2 are sold without approval and their identity and purity are unverified. Its long-term safety in humans remains an open question.
Melanotan-2, also written Melanotan II, is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, and the lactam bridge between the aspartate and lysine side chains constrains the peptide into a ring. This structural change increases receptor affinity and metabolic stability relative to the native hormone. The compound was created in the 1980s as a research tool for studying pigmentation biology.
Nanostructured lipid carriers (NLCs) are lipid-based nanoparticles that contain a mixture of solid and liquid lipids in the central core of the lipid carrier. NLCs are derived from SLNs by injecting liquid lipids into the solid core, resulting in a non-uniform internal core. This modification allows for higher drug capacity and more controlled drug delivery.
==== X-Ray Absorption Spectroscopy ==== X-Ray absorption spectroscopy (XAS) has been demonstrated as a technique for nuclear forensic investigations involving uranium speciation. Both the lower energy near-edge (XANES) and higher energy fine structure (EXAFS) analytical methods may be useful for this type of characterisation. Typically, XANES is employed to determine the oxidation state of the absorbing uranium atom, while EXAFS can be used to determine its local atomic environment. This spectroscopic method, when coupled with X-Ray diffraction (XRD), would be of most benefit to complex nuclear forensic investigations involving species of different oxidation states.
=== Derivatives === Identified uses for DMPEA includes the following list of agents: 1. Bevantolol. 2. Bisobrin 3. Bometolol 4. Buquiterine 5. Denopamine 6. Dobutamine 7. Dopamine 8. Dopexamine 9. Dramedilol 10. Drotaverine 11. Ecastolol 12. Falipamil 13. Gallopamil 14. Methopholine 15. Mixidine 16. Mefeclorazine 17. Nigellimine [4594-02-9] 18. Nuciferine 19. Papaverine 20. Tetrabenazine 21. Tiapamil 22. Trimethoquinol 23. Veradoline 24. Verapamil.
Both these levels are raised to be close in energy to the 7s ones, high enough to possibly be chemically active. This would allow for the possibility of exotic nihonium compounds without lighter group 13 analogues. Periodic trends would predict nihonium to have an atomic radius larger than that of thallium due to it being one period further down the periodic table, but calculations suggest nihonium has an atomic radius of about 170 pm, the same as that of thallium, due to the relativistic stabilisation and contraction of its 7s and 7p1/2 orbitals. Thus, nihonium is expected to be much denser than thallium, with a predicted density of about 16 to 18 g/cm3 compared to thallium's 11.85 g/cm3, since nihonium atoms are heavier than thallium atoms but have the same volume. Bulk nihonium is expected to have a hexagonal close-packed crystal structure, like thallium. The melting and boiling points of nihonium have been predicted to be 430 °C and 1100 °C respectively, exceeding the values for indium and thallium, following periodic trends. Nihonium should have a bulk modulus of 20.8 GPa, about half that of thallium (43 GPa).
Sources: en.wikipedia.org
== Society and culture == The American TV show, Diagnosis, in episode 1 Detective Work, an athletic 23-year-old nursing student, Angel Parker, experiences episodes of extreme muscle fatigue, pain and cramping after prolonged exercise, sometimes followed by dark urine (myoglobinuria) and elevated CK (rhabdomyolysis). These episodes can leave her immobile for hours. She had experienced muscle pains since childhood, passed-off as "growing pains." Her first hospitalization was at age 14, for intolerable leg pain that woke her in the middle of the night, sobbing uncontrollably from the intense pain. After multiple hospitalizations for myoglobinuria and rhabdomyolysis, many misdiagnoses, and many different doctors and tests that were unable to give an explanation for her symptoms, through the assistance of the show genetic sequencing confirmed that she had CPT-II deficiency (a fatty-acid metabolism disorder). In 2010, Walk over Wales (WoW), the first walking course for those with muscle glycogen storage disease occurred to teach participants activity adaptations, swap notes, and raise public awareness. Led by Andrew Wakelin, participants came from around the world, including Stacey Reason, Dan Chambers, Andy Williams, Charlton Thear and Dr. Ros Quinlivan. From Great Orme to Cardiff Bay, in 32 days they walked 210 miles (338 km) and ascended approximately 35,000 feet (10,700 metres) through Snowdonia National Park, the Cambrian Mountains, and Brecon Beacons National Park.
=== Portugal === The Portuguese parliament is called the Assembleia da República. A member of parliament is known as a deputado, that is, a person who is appointed through democratic election to act on the people's behalf.
parietina has more limited genetic exchange between nearby populations than previously thought, possibly due to habitat specialization. Molecular investigations into the mating-type (MAT) loci have further revealed the reproductive strategies within Xanthoria. While X. parietina is homothallic—possessing only a MAT1-2 gene (although truncated)—species such as X. polycarpa are heterothallic, with distinct MAT idiomorphs (different mating-type genetic regions). These differences in mating system structure can significantly affect population genetics, influencing levels of genetic diversity, gene flow, and ultimately speciation processes within the genus.
Sources: en.wikipedia.org
The dry powder is more stable during transport and storage than a solution. It also allows a known amount of material to be reconstituted at a chosen concentration.
Most certificates state a percentage derived from chromatographic peak area, alongside a mass confirmation. The exact criteria and acceptance thresholds vary between laboratories.
Dry powder is kept frozen or refrigerated and protected from light and moisture. Solutions are handled cold and used promptly to limit degradation.
It is a synthetic cyclic heptapeptide and an analogue of alpha-melanocyte-stimulating hormone. The molecule is produced by chemical synthesis rather than extracted from a biological source.